Mrs. Jennalyn Apostol Wooldridge, LVN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1270 Natividad Rd, Salinas, CA 93906 Phone: 831-417-9796 |
Rita Elaine Turcotte, LVN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1441 Constitution Blvd Ste 202, Salinas, CA 93906 Phone: 831-905-3245 |
Leila Andrade, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Casentini St, Salinas, CA 93907 Phone: 831-758-9457 |
Genia Towner-diaz, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1441 Constitution Blvd Ste 202, Salinas, CA 93906 Phone: 831-769-0552 |
Kathleen Marie Mcguiness, NP Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 335 Katherine Ave, Salinas, CA 93901 Phone: 831-422-7275 |
News Archive
Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.
Sara Algoe of the University of North Carolina-Chapel Hill who has investigated how gratitude benefits close relationships, including how expressing gratitude leads to long-term social outcomes for women with metastatic breast cancer and the evolutionary role for gratitude. She will be presenting some of this work at the SPSP annual meeting in New Orleans (Jan. 17-19, 2013), and she is a recipient of grant funding through the Expanding the Science and Practice of Gratitude project.
A new study of a quarter-million Miami-Dade County Medicare beneficiaries showed that higher levels of neighborhood greenness, including trees, grass and other vegetation, were linked to a significant reduction in the rate of chronic illnesses, particularly in low-to-middle income neighborhoods.
Bayer today announced positive data on its investigational compound copanlisib, an intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
› Verified 3 days ago